Effects of Salivae Miltiorrhizae Liguspyragine Hydrochloride and Glucose Injection ((sic)) on the Levels of Main Platelet Thrombin Receptors in Chronic Haemodialysis Patients
Effects of Salivae Miltiorrhizae Liguspyragine Hydrochloride and Glucose Injection ((sic)) on the Levels of Main Platelet Thrombin Receptors in Chronic Haemodialysis Patients
复制标题
DOI：
10.1007/s11655-011-0826-8
复制
发表时间：
2011-08-01
影响因子：
2.9
通讯作者：
Liu Jan-guo
中科院分区：
文献类型：
--
作者：
Li Yan;Shen Lin;Liu Jan-guo
目的：目的探讨丹参注射液对慢性血液透析（HD）终末期肾病（ESRD）患者血小板膜受体蛋白酶激活受体1（PAR 1）和蛋白酶激活受体4（PAR 4）表达的影响。方法：86例终末期肾病血液透析患者（治疗组），采用SLGI治疗，7 d为1个疗程，连续治疗2个疗程。既往治疗不变。采用流式细胞术检测患者血小板PAR 1、PAR 4的表达，浊度法测定血小板最大聚集率（MAR）。同时测定肾功能。并与治疗前及正常对照组（54例健康受试者）进行比较。结果如下：与正常对照组相比，ESRD HD患者治疗前PAR 1、PAR 4和血小板MAR表达均显著升高（P=0.001，P=0.006，P=0.008）;经SLGI治疗后，患者上述指标均明显下降（P=0.036和P=0.046），除PAR 4（P=0.067）外，均高于正常对照组，但无统计学意义。结论：（1）PAR 1和PAR 4的过度表达可能导致血小板聚集性增加，这可能是ESRD患者HD时血栓形成的原因之一。(2)SLGI能够下调ESRD HD患者PAR 1的表达，改善血小板功能，调节血小板活化。
Objective: To investigate the effects of Salvia Miltiorrhiza Liguspyragine Hydrochloride and Glucose Injection ((sic), SLGI) on the expression of platelet membrane receptors proteinase-activated receptor-1 (PAR1) and proteinase-activated receptor-4 (PAR4) in end-stage renal disease (ESRD) patients on chronic haemodialysis (HD). Methods: Eighty-six ESRD patients on HD (treated group) were treated with SLGI, 7 days as one therapeutic course, for two successive courses. The previous therapies were unchanged. Flow cytometry was used to assess the expression of platelet PAR1 and PAR4 in the patients, and turbidity method was used to determine the platelet maximum aggregation rate (MAR). Meanwhile, renal function was measured. The final data were compared with those before treatment and with those in the normal control group (54 healthy subjects). Results: Compared with the normal control group, the expressions of PAR1 and PAR4 and platelet MAR in ESRD patients on HD was significantly higher before treatment (P=0.001, P=0.006, and P=0.008); after treatment with SLGI, the above indices in patients were remarkably decreased (P=0.036 and P=0.046), except PAR4 (P=0.067), but still higher than those in the normal control group, however, it was not statistically significant. Conclusions: (1) The overexpression of PAR1 and PAR4 might lead to increased platelet aggregation and this could be one of the reasons for the thrombotic events in ESRD patients on HD. (2) SLGI was able to down-regulate the expression of PAR1 in ESRD patients on HD, improve platelet function, and regulate platelet activation.